Catalog No.S1198 Synonyms: CPT-11

Irinotecan Chemical Structure

Molecular Weight(MW): 586.68

Irinotecan is a topoisomerase I inhibitor for LoVo cells and HT-29 cells with IC50 of 15.8 μM and 5.17 μM, respectively.

Size Price Stock Quantity  
In DMSO USD 90 In stock
USD 70 In stock
USD 120 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Biomaterials, 2015, 72:74-89.. Irinotecan purchased from Selleck.

    Growth inhibitory effects of Irinotecan in human pancreatic cancer cells. Panc1 cells were plated in triplicates into 48-well plates at a density of 10,000 cells/ml. After 24 hours, complete culture medium was changed into fresh low-serum-containing medium (1% FBS) containing DMSO (control) or indicated doses of Irinotecan (Selleckchem). Cell viability 72 hours after treatment was determined by AlamarBlue assay (Invitrogen) according to manufacturer's instructions. Results are expressed as percentages of control, which was arbitrarily assigned 100% viability, and represented as the mean ± standard deviation (SD) of the tripicate wells. 

    Dr. Mikhail Menshikov of Cardiology Research Center. Irinotecan purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Click to view more


2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Irinotecan is a topoisomerase I inhibitor for LoVo cells and HT-29 cells with IC50 of 15.8 μM and 5.17 μM, respectively.
Features Irinotecan is a prodrug that is used to treat metastatic colorectal cancer.
Topo I [1]
(LoVo, HT-29 cells)
In vitro

Irinotecan is activated to SN-38 by carboxylesterases to become able to interact with its target, topoisomerase I. Irinotecan induces similar amounts of cleavable complexes at its IC50 in LoVo cells and HT-29 cell lines. SN-38 induces a concentration-dependent formation of cleavable complexes, which is not significantly different in LoVo cells and HT-29 cell lines. Cell accumulation of Irinotecan is markedly different, reaching consistently higher levels in HT-29 cells than in LoVo cells. [1] The lactone E-ring of Irinotecan and SN-38 hydrolyses reversibly in aqueous solutions, and the interconversion between the lactone and carboxylate forms is dependent on pH and temperature. Liver is primarily responsible for the activation of Irinotecan to SN-38. At equal concentrations of Irinotecan and SN-38 glucuronide, the rate of beta-glucuronidase-mediated SN-38 production is higher than that formed from Irinotecan in both tumour and normal tissue. [2] Irinotecan is also converted to SN-38 in intestines, plasma and tumor tissues. [3] Irinotecan is significantly more active in SCLC than in NSCLC cell lines, whereas no significant difference between histological types is observed with SN-38. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT116 NV;sZpc4[3m2b4TvfIlkcXS7IHHzd4F6 MYixNEDPxE1? MlvkSG1UVw>? NE\WSnJKTDVyPUW0NEBvVQ>? NIPIWWwyOTl4NUO2Ni=>
MCF-7ADR NXyzR492[3m2b4TvfIlkcXS7IHHzd4F6 NVrzd5VLOTBizszN M{TEZmROW09? NV7ydpNXUUR3ME61NFAhdk1? MnTzNVE6PjV|NkK=
L1210 MVXjfZRwfG:6aXPpeJkh[XO|YYm= MkjGTWM2OD1zLkKgxtVO MlizNVg1Pjl{Mx?=
RPMI8402 MnvoZ5l1d3SxeHnjbZR6KGG|c3H5 NFfaZ5YyODBizszN NVHsZ4NJUUN3ME21O|Ahdk1? NGXvZlQyOjd2N{e5PC=>
A-549 MUHjfZRwfG:6aXPpeJkh[XO|YYm= M1nvVZ4zOCEQvF2= MmL5SG1UVw>? NUTacndMUUN3ME22MlUzQCEQvF2= MXqxPFIxPzd2OB?=
LOVO NXPqZm5E[3m2b4TvfIlkcXS7IHHzd4F6 MUj+NlAh|ryP NVnre2E4TE2VTx?= MVXJR|UxRTlwMEG1JO69VQ>? NHT4PIsyQDJyN{e0PC=>
MCF7 NIL4eZZkgXSxdH;4bYNqfHliYYPzZZk> NHrjbo5,OjBizszN NWXBOnJbTE2VTx?= M4jNc2lEPTB;MUeuOFA{KM7:TR?= Mor4NVgzODd5NEi=
LS174T MXLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? MXjEUXNQ MkDnTWM2OD1zLkG2JO69VQ>? M3jvVFE5PDd7MUG4
KB3-1 NX3FUY1q[3m2b4TvfIlkcXS7IHHzd4F6 MonyTWM2OD1yLk[4JO69VQ>? M4HjdlE5PzdzOUOw
KBH5.0 NF7hTGhkgXSxdH;4bYNqfHliYYPzZZk> M1:yfWlEPTB;Nz60JO69VQ>? NYT4RYRIOTh5N{G5N|A>
Hep G2 MnXNS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MkKzglExKM7:TR?= MVjEUXNQ M3zkfmlEPTB;NT65OEDPxE1? MWGxPVc6Pjl3Nh?=
Hep 3B MlzHS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? NFvXOJJ,OTBizszN MX3EUXNQ NWO1OIlpUUN3ME20Mlc{KM7:TR?= MXuxPVc6Pjl3Nh?=
Hep 2.2. NUnQUGt5T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= MnPLglExKM7:TR?= M{\qWWROW09? NFrr[ppKSzVyPkGwJO69VQ>? NFKwfIEyQTd7Nkm1Oi=>
A549 NWXNOG1p[3m2b4TvfIlkcXS7IHHzd4F6 M1fl[WROW09? NVnse2FVUUN3ME20MlYyKM7:TR?= MlH2NlA{PzFzOEO=
MDA-MB-435 M{PnOIN6fG:2b4jpZ4l1gSCjc4PhfS=> NHHpd|hFVVOR MkT5TWM2OD1zLkG0JO69VQ>? NVe1VWQ4OjB|N{GxPFM>
LOVO Mlj1Z5l1d3SxeHnjbZR6KGG|c3H5 M3LZdGROW09? NUPaO4lvUUN3ME20Mlk6KM7:TR?= NGnvV20zODN5MUG4Ny=>
MDA-MB-435 M{fsOoN6fG:2b4jpZ4l1gSCjc4PhfS=> MmnlSG1UVw>? M3P0PGlEPTB;MUeg{txO NXXFb5BROjB7NEK0PVA>
NCI60 MmK3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? M{X0fmROW09? MmDMS2k2OD1zND6xNlU1KM7:TR?= MmLnNlExOzV|M{S=
H460 M3zzeoN6fG:2b4jpZ4l1gSCjc4PhfS=> MonpSG1UVw>? MV;JR|UxRTBwMEG1JO69VQ>? NXjaOmprOjF|NEG2O|Q>
PC-3 MknPZ5l1d3SxeHnjbZR6KGG|c3H5 MWXEUXNQ NIjwe|dKSzVyPUCuNlIh|ryP MVeyNVM1OTZ5NB?=
SK-MEL-2 M3TEfIN6fG:2b4jpZ4l1gSCjc4PhfS=> M{mzN2ROW09? NX7JZY45UUN3ME2wMlEh|ryP MW[yNVM1OTZ5NB?=
A375 NV3qfnZG[3m2b4TvfIlkcXS7IHHzd4F6 NIL1XmFFVVOR M{LhOGlEPTB;MD6wNFQh|ryP NFv0VVczOTN2MU[3OC=>
DU 145 NYG0[pNG[3m2b4TvfIlkcXS7IHHzd4F6 NUX0Tm91TE2VTx?= MofNTWM2OD1yLkKg{txO MnHqNlE{PDF4N{S=
LNCaP M{PlXIN6fG:2b4jpZ4l1gSCjc4PhfS=> NYWw[FNTTE2VTx?= NF:3elBKSzVyPUCuNFA6KM7:TR?= NVzoUotJOjF|NEG2O|Q>
KB-vin MnrSZ5l1d3SxeHnjbZR6KGG|c3H5 MWf+NlAh|ryP Ml3mSG1UVw>? NWfHTYF5UUN3ME6yNEDPxE1? NWfONY4yOjJyN{myOVQ>

... Click to View More Cell Line Experimental Data

In vivo In COLO 320 xenografts, Irinotecan induces a maximum growth inhibition of 92%. [5] A single dose of Irinotecan significantly increases amounts of topoisomerase I covalently bound to DNA in stomach, duodenum, colon and liver. Concomitantly, the Irinotecan-treated group shows significantly higher amounts of DNA strand breaks in colon mucosa cells compared to the control group. [6]


Cell Research:


+ Expand
  • Cell lines: LoVo and HT-29 cells
  • Concentrations: 0 μM -100 μM
  • Incubation Time: 48 hours
  • Method:

    Exponentially growing cells (LoVo and HT-29 cells) are seeded in 20 cm2 Petri dishes with an optimal cell number for each cell line (2 × 104 for LoVo cells, 105 for HT-29 cells). They are treated 2 days later with increasing concentrations of Irinotecan or SN-38 for one cell doubling time (24 hours for LoVo cells, 40 hours for HT-29 cells). After washing with 0.15 M NaCl, the cells are further grown for two doubling times in normal medium, detached from the support with trypsin-EDTA and counted in a hemocytometer. The IC50 values are then estimated as the Irinotecan or SN-38 concentrations responsible for 50% growth inhibition as compared with cells incubated without Irinotecan or SN-38.

    (Only for Reference)
Animal Research:


+ Expand
  • Animal Models: Female nude mice with COLO 320 and WiDr xenografts
  • Formulation: 0.9% NaCl
  • Dosages: 20 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 7 mg/mL (11.93 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 586.68


CAS No. 97682-44-5
Storage powder
in solvent
Synonyms CPT-11

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01928290 Recruiting Stomach Neoplasms|Esophageal Neoplasms Washington University School of Medicine November 8, 2013 Phase 2
NCT01336985 Terminated Neoplasm Metastases|Melanoma|Colorectal Neoplasms National Institutes of Health Clinical Center (CC) March 28, 2011 Phase 1
NCT02316496 Terminated Colorectal Cancer Metastatic Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) September 23, 2015 Phase 2
NCT02975882 Not yet recruiting Childhood Solid Neoplasm|Recurrent Central Nervous System Neoplasm|Recurrent Solid Neoplasm|Refractory Central Nervous System Neoplasm Childrens Oncology Group|National Cancer Institute (NCI) September 2017 Phase 1
NCT03009058 Not yet recruiting Metastatic Cancer Immodulon Therapeutics Ltd January 2017 Phase 1|Phase 2
NCT03017326 Not yet recruiting Hepatoblastoma|Carcinoma, Hepatocellular University of Birmingham|Fundació Institut Germans Trias i Pujol|University of Padua|University of Newcastle Upon-Tyne|University Hospital Munich|University Hospital, Bonn|University of Kiel|University Hospital Tuebingen|Medical University of Gdansk January 2017 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Irinotecan | Irinotecan supplier | purchase Irinotecan | Irinotecan cost | Irinotecan manufacturer | order Irinotecan | Irinotecan distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID